NYSE - Nasdaq Real Time Price USD

Arcus Biosciences, Inc. (RCUS)

13.30

-0.08

(-0.60%)

As of 10:44:50 AM EST. Market Open.

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif., January 24, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 31,800 shares of the Company’s common stock at an exercise price per share of $13.33, which was the closing price on January 23, 2024, and

Business Wire 6 days ago

RCUS
-0.60%
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

HAYWARD, Calif., January 21, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus’s responsi

Business Wire 9 days ago

RCUS
-0.60%
Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?

Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 23 days ago

MRNA

RCUS
-0.60%
Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...

Simply Wall St. last month

RCUS
-0.60%
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

HAYWARD, Calif., December 19, 2024--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Tuesday, January 14th, 2025, at 3:45pm PT.

Business Wire last month

RCUS
-0.60%
Arcus Biosciences to Participate in Two Upcoming Investor Conferences

HAYWARD, Calif., November 19, 2024--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December:

Business Wire 2 months ago

RCUS
-0.60%
Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report

Arcus Biosciences, Inc. ( NYSE:RCUS ) defied analyst predictions to release its third-quarter results, which were ahead...

Simply Wall St. 2 months ago

RCUS
-0.60%
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...

Arcus Biosciences Inc (RCUS) reports robust financial health and strategic advancements in late-stage trials, despite facing competitive and strategic challenges.

GuruFocus.com 2 months ago

RCUS
-0.60%
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 6.54% and 43.97%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

RCUS
-0.60%
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

HAYWARD, Calif., November 06, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a pipeline update on its clinical-stage investigational molecules — targeting TIGIT, HIF-2a, CD73, the A2a/A2b receptors, CD-39, AXL and PD-1 — across multiple common cancers.

Business Wire 2 months ago

RCUS
-0.60%
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

HAYWARD, Calif., November 05, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, (DZ) versus zimberelimab (Z) or chemotherapy in patients with fro

Business Wire 2 months ago

RCUS
-0.60%
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates

Regeneron (REGN) delivered earnings and revenue surprises of 6.04% and 1.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

REGN

RCUS
-0.60%
Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for

Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 3 months ago

RCUS
-0.60%
DNLI
-0.49%
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

HAYWARD, Calif., October 30, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced four accepted abstracts at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place in Houston, Texas, November 6 – 10, 2024.

Business Wire 3 months ago

RCUS
-0.60%
Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 11.90% and 9.84%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

EXEL

RCUS
-0.60%
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

HAYWARD, Calif., October 24, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today presented the first clinical activity data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics i

Business Wire 3 months ago

RCUS
-0.60%
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

HAYWARD, Calif., October 22, 2024--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Wednesday, November 6th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company’s financial results and pipeline update for the quarter ended September 30th, 2024.

Business Wire 3 months ago

RCUS
-0.60%
Arcus Biosciences Inc (RCUS) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...

Arcus Biosciences Inc (RCUS) showcases robust financial health and strategic progress in Phase 3 trials, despite a notable drop in quarterly revenue.

GuruFocus.com 3 months ago

RCUS
-0.60%
Arcus Biosciences, Inc.'s (NYSE:RCUS) Intrinsic Value Is Potentially 30% Above Its Share Price

Key Insights The projected fair value for Arcus Biosciences is US$22.75 based on 2 Stage Free Cash Flow to Equity...

Simply Wall St. 3 months ago

RCUS
-0.60%
Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

HAYWARD, Calif., October 09, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced four accepted abstracts at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024, in Barcelona, Spain. The data being presented include a growing body of evidence supporting the potential of casdatifan as a b

Business Wire 3 months ago

RCUS
-0.60%

Performance Overview

Return	RCUS	S&P 500
YTD	-10.80%	+3.53%
1-Year	-15.39%	+24.17%
3-Year	-55.29%	+37.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?

Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report

Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates

Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Arcus Biosciences Inc (RCUS) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...

Arcus Biosciences, Inc.'s (NYSE:RCUS) Intrinsic Value Is Potentially 30% Above Its Share Price

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Performance Overview